BiondVax Pharmaceuticals Ltd ADR (BVXV)

3.62
-0.45(-11.06%)
After Hours
3.65
+0.03(+0.83%)
- Real-time Data
  • Volume:
    446,296
  • Bid/Ask
    3.50/3.60
  • Day's Range
    3.50 - 4.05

BVXV Overview

Prev. Close
3.62
Day's Range
3.5 - 4.05
Revenue
0
Open
3.92
52 wk Range
2.35 - 62
EPS
-1.26
Volume
446,296
Market Cap
56.85M
Dividend (Yield)
N/A (N/A)
Average Volume (3m)
1,183,860
P/E Ratio
N/A
Beta
2.41
1-Year Change
-56.85%
Shares Outstanding
11,536,294
Next Earnings Date
28 Apr 2021
What is your sentiment on BiondVax Pharmaceuticals Ltd ADR?
or
Market is currently closed. Voting is open during market hours.

BiondVax Pharmaceuticals Ltd ADR News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

BiondVax Pharmaceuticals Ltd ADR Company Profile

BiondVax Pharmaceuticals Ltd ADR Company Profile

Employees
17

BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.